Physician profile
Robyn Arlean Thirkill
NPI 1467144907
$3,303.49
in general payments reported to CMS, 2019-2025
24 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 96% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $534 · 2024: $1,388 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $669.22 | 2023-2025 | |
| Pfizer INC. | $450.17 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $368.18 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $358.27 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.61 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $199.04 | 2024-2025 | |
| Abbott Laboratories | $141.14 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $130.53 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Gilead Sciences, INC. | $117.79 | 2023-2025 | Yeztugo |
| Organon LLC | $113.03 | 2023-2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $110.92 | 2023 | Rexulti |
| Amgen INC. | $88.39 | 2023-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $57.29 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $56.66 | 2025 | General - Pain Management |
| Lundbeck LLC | $43.56 | 2024-2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $37.31 | 2024-2025 | Cologuard Collection Kit |
| Indivior INC. | $22.34 | 2025 | Sublocade |
| Neurocrine Biosciences, INC. | $21.35 | 2024 | Ingrezza |
| Esperion Therapeutics, INC. | $18.49 | 2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $18.41 | 2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $17.20 | 2025 | Arexvy, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $15.43 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Xeris Pharmaceuticals, INC. | $14.59 | 2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $14.57 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Thirkill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.